Table 1 Baseline characteristics
| Â | All patients | % Patients with the highest expected lifetime benefit | % Patients with the highest expected 10-year risk reduction | ||||
|---|---|---|---|---|---|---|---|
n = 10,000 | n = 500 | n = 1000 | n = 2000 | n = 500 | n = 1000 | n = 2000 | |
Age (years) | 61 (8) | 51 (5) | 52 (5) | 54 (6) | 65 (8) | 64 (8) | 64 (8) |
Male gender | 7366 (74%) | 274 (55%) | 598 (60%) | 1259 (63%) | 346 (69%) | 718 (72%) | 1479 (74%) |
Current smoking | 3137 (31%) | 116 (23%) | 240 (24%) | 531 (27%) | 242 (48%) | 471 (47%) | 907 (45%) |
Type 2 diabetes mellitus | 1775 (18%) | 46 (9%) | 105 (11%) | 210 (11%) | 144 (29%) | 280 (28%) | 506 (25%) |
Systolic blood pressure (mmHg) | 140 (20) | 142 (21) | 141 (21) | 140 (21) | 150 (22) | 148 (22) | 146 (22) |
Total cholesterol (mmol/L) | 4.7 (4.0–5.6) | 6.6 (5.9– 7.2) | 6.2 (5.6–6.9) | 5.9 (5.2–6.6) | 6.9 (6.3–7.6) | 6.4 (5.8–7.1) | 6.0 (5.3–6.7) |
Creatinine (umol/L) | 89 (70–111) | 90 (75–108) | 90 (74–111) | 90 (72–110) | 107 (86–129) | 106 (85–128) | 103 (84–125) |
1 location of CVD | 7929 (79%) | 414 (83%) | 828 (83%) | 1636 (82%) | 284 (57%) | 602 (60%) | 1288 (64%) |
2 location of CVD | 1998 (20%) | 86 (17%) | 172 (17%) | 359 (18%) | 211 (42%) | 386 (39%) | 696 (35%) |
3 location of CVD | 73 (1%) | 0 (0%) | 0 (0%) | 5 (0%) | 5 (1%) | 12 (1%) | 16 (1%) |
Coronary heart disease | 6191 (62%) | 314 (63%) | 627 (63%) | 1253 (63%) | 339 (68%) | 659 (66%) | 1295 (65%) |
Cerebrovascular disease | 3110 (31%) | 140 (28%) | 299 (30%) | 600 (30%) | 155 (31%) | 314 (31%) | 663 (33%) |
Peripheral artery disease | 1924 (19%) | 84 (17%) | 163 (16%) | 344 (17%) | 130 (26%) | 258 (26%) | 467 (23%) |
Abdominal aortic aneurysm | 919 (9%) | 48 (10%) | 83 (8%) | 172 (9%) | 97 (19%) | 179 (18%) | 303 (15%) |
Atrial fibrillation | 278 (3%) | 1 (0%) | 3 (0%) | 6 (0%) | 32 (6%) | 65 (7%) | 106 (5%) |
Chronic heart faillure | 486 (5%) | 7 (1%) | 15 (2%) | 42 (2%) | 61 (12%) | 117 (12%) | 190 (10%) |